Uveal Melanoma
Symptoms, Doctors, Treatments, Advances & More

Uveal Melanoma Overview

Save information for later
Sign Up

Learn About Uveal Melanoma

What is the definition of Uveal Melanoma?
Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract. The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases of Intraocular melanoma develop in the choroid, called choroidal melanoma. The ciliary body is less commonly a site of origin, and the iris is the least common. Each manifests with different clinical features and symptoms.
What are the alternative names for Uveal Melanoma?
  • Intraocular melanoma
  • Melanoma of the Uvea
  • Uveal melanoma
Who are the top Uveal Melanoma Local Doctors?
Carol L. Shields
Elite in Uveal Melanoma
Dr. Carol L. Shields
Ophthalmology | Oncology
Elite in Uveal Melanoma
Dr. Carol L. Shields
Ophthalmology | Oncology

Ophthalmology - Wills Eye Hospital

840 Walnut Street, Floor 10, 
Philadelphia, PA 
215-928-3105
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carol Shields is an Oncologist and an Ophthalmologist in Philadelphia, Pennsylvania. Dr. Shields is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Retinoblastoma, Melanoma of the Eye, Uveal Melanoma, Vitrectomy, and Iridectomy. Dr. Shields is currently accepting new patients.

Takami Sato
Elite in Uveal Melanoma
Dr. Takami Sato
Hematology | Oncology
Elite in Uveal Melanoma
Dr. Takami Sato
Hematology | Oncology
111 South 11th Street, The Bodine Center, 
Philadelphia, PA 
Languages Spoken:
English, Japanese
See accepted insurances
Accepting New Patients
Offers Telehealth

Takami Sato is an Oncologist in Philadelphia, Pennsylvania. Dr. Sato is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. His top areas of expertise are Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, Liver Embolization, and Osteotomy. Dr. Sato is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Marlana M. Orloff
Elite in Uveal Melanoma
Dr. Marlana M. Orloff
Hematology | Oncology
Elite in Uveal Melanoma
Dr. Marlana M. Orloff
Hematology | Oncology

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
215-955-8874
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marlana Orloff is an Oncologist in Philadelphia, Pennsylvania. Dr. Orloff has been practicing medicine for over 17 years and is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. Her top areas of expertise are Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, Melanoma, and Liver Embolization. Dr. Orloff is currently accepting new patients.

View All Doctors
What are the latest Uveal Melanoma Clinical Trials?
Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Who is this study for: Patients with Melanoma
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Procedure, Biological, Other
Study Drugs: Cyclophosphamide, Fludarabine Phosphate, IL13Ralpha2-Specific Hinge-Optimized 4-1BB-co-Stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Recombinant Interleukin-2
Study Phase: Phase 1

Summary: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Enrollment Status: Recruiting
Publish Date: February 04, 2026
Intervention Type: Biological
Study Phase: Phase 1

Summary: This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center